D-0162-2023 Class III Terminated

Recalled by MACLEODS PHARMA USA, INC — Princeton, NJ

FDA drug recall D-0162-2023 was initiated by MACLEODS PHARMA USA, INC on Jan 5, 2023 and is designated Class III. Reason for recall: Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles. The recall status is terminated (terminated Jun 24, 2025). Affected quantity: 10052 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 25, 2023
Initiation Date
Jan 5, 2023
Termination Date
Jun 24, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10052 bottles

Product description

Levofloxacin Tablets, USP 500 mg; 50-count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540; Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-022-08

Reason for recall

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Distribution pattern

Nationwide within United States and Puerto Rico.

Code information

Lot #: BLF2214A; Exp. 06/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0162-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0162-2023. Report a data issue: hello@regdatalab.com.